Royal UNIBREW A/S
Share buy-back program
Share buy-back program
COMPANY ANNOUNCEMENT NO 54/2025 - November 3, 2025
On August 26, 2025, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 44/2025.
The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, as amended (the Market Abuse Regulation - MAR) and the Commission Delegated Regulation (EU) No 2016/1052 of March 8, 2016.
The share buy-back program is expected to be realized in the period from August 27, 2025, to December 19, 2025. The total transaction value of the share buy-backs in the period will not exceed DKK 300m.
The following transactions on Nasdaq Copenhagen A/S have been made under the program:
| Number of Shares | Average purchase price DKK | Transaction value, DKK | |
| Accumulated, last announcement | 395,500 | 486.54 | 192,425,655 |
| October 27, 2025 | 5,000 | 497.02 | 2,485,100 |
| October 28, 2025 | 5,000 | 497.00 | 2,485,000 |
| October 29, 2025 | 5,000 | 494.70 | 2,473,500 |
| October 30, 2025 | 7,000 | 490.92 | 3,436,440 |
| October 31, 2025 | 7,000 | 488.49 | 3,419,430 |
| Total accumulated under the program | 424,500 | 486.98 | 206,725,125 |
With the transactions stated above Royal Unibrew owns a total of 1,027,542 shares, corresponding to 2% of the share capital. The total amount of shares in the company is 50,200,000, including treasury shares.
For further information please contact:
Flemming Ole Nielsen (Head of Investor Relations)
E-mail: Flemming.Nielsen@royalunibrew.com
Telephone: +45 25 41 68 04
Encl.
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Basilea Pharmaceutica AG, Allschwil4.11.2025 07:15:00 CET | Press release
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
Novartis Pharma AG4.11.2025 07:15:00 CET | Press release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Tealium Inc.4.11.2025 07:00:00 CET | Press release
Tealium appoints Nick Martin as General Manager for EMEA
Wereldhave N.V.4.11.2025 07:00:00 CET | Press release
Wereldhave Trading update Q3 2025
dsm-firmenich4.11.2025 07:00:00 CET | Press release
Weekly progress on share repurchase program to cover share plans and reduce capital
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom